Biodesix, Inc.

BDSX Healthcare Diagnostics & Research

Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.66 1.05 −4.25%
Market cap
$260.7M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
−7.46
Beneish M
−3.13
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Piotroski F-Score
4 4 4 3 3 4 — — —
P/S ratio
0.58 2.78 2.98 2.26 2.66 2.14 0.13 0.13 —
Altman Z-Score
(7.46) (5.23) (5.77) (5.72) (4.84) (1.97) — — —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Altman Z″-Score (non-manufacturers)
(19.59) (15.90) (16.14) (14.10) (14.92) (4.77) (22.77) (25.92) —
P/Operating CF
66.00 (48.34) (11.90) (7.22) (14.20) (11.14) (0.94) (0.94) —
Beneish M-Score
(3.13) (1.92) (3.50) (3.19) (3.80) (1.35) (2.17) — —
P/B ratio
0.00 9.48 31.91 4.19 7.34 2.37 0.00 0.00 —
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 7.58 0.00 0.00 —
EV/Sales
0.90 2.92 3.16 1.79 2.24 1.39 1.92 1.92 —
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
EV/Operating CF
(3.43) (4.28) (6.78) (1.52) (4.33) (2.96) (2.80) (2.80) —
EV/FCF
(3.37) (4.00) (3.38) (1.41) (3.97) (2.68) (2.50) (2.50) —
Quick Ratio
1.61 2.43 1.02 2.11 1.26 2.41 0.47 1.79 —
Current Ratio
1.87 2.76 1.19 2.34 1.51 2.68 0.56 2.22 —
Net Debt/EBITDA
(1.36) (0.39) (0.29) 0.46 0.65 2.42 (1.30) (1.04) —
Debt/Assets
54.24% 37.46% 35.60% 26.97% 13.16% 22.93% 79.88% 59.14% 0.00%
Debt/Equity
(19.25) 1.75 7.70 1.22 0.51 0.67 (0.16) (0.12) —
Asset Turnover
0.96 0.73 0.51 0.45 0.55 0.55 0.58 1.05 —
Operating CF/Net income
0.66 1.13 0.44 0.69 0.65 0.68 0.71 0.68 —
Capex/Depreciation
(0.06) (0.42) (2.16) (0.32) (0.43) (0.25) (0.44) 0.00 —
Interest Coverage
(3.61) (4.18) (4.34) (6.27) (9.08) (3.02) (8.89) (12.29) —
ROE
(383.09%) (337.30%) (414.09%) (324.53%) (141.75%) 34.08% 14.52% 12.37% —
ROA
(38.18%) (43.73%) (54.32%) (77.45%) (43.78%) (37.75%) (73.08%) (133.99%) —
ROIC
(67.00%) (69.42%) (190.38%) (1,229.75%) 0.00% (210.60%) 0.00% 0.00% —
Return on Tangible Assets
(88.39%) (81.01%) (152.77%) (180.08%) (229.18%) (54.81%) 394.94% (382.94%) —
Average Days of Receivables
37.27 44.03 57.10 48.38 24.48 122.61 78.67 33.80 —
Research and Development Expense of Revenue
13.56% 13.40% 20.35% 34.29% 23.46% 23.75% 42.64% 40.07% —
Selling, General and Administrative Expense of Revenue
98.92% 112.80% 137.28% 160.84% 92.68% 76.51% 124.78% 126.76% —
Intangible Assets out of Total Assets
0.22 0.22 0.23 0.27 0.35 0.23 0.67 0.71 0.00
Share Based Compensation of Revenue
4.68% 9.31% 10.95% 15.60% 9.07% 8.14% 0.69% 0.00% —
Graham Net Nets
(1.12) (0.19) (0.38) (0.22) (0.09) 0.06 (79.63) (79.63) —
Graham Number
5.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Earnings Yield
(71.32%) (22.88%) (36.52%) (77.56%) (29.68%) (493.17%) (774.27%) (774.27%) —
Free Cash Flow Yield
(46.11%) (26.31%) (31.45%) (56.20%) (21.25%) (24.14%) (577.14%) (577.14%) —
Revenue per Share
11.72 11.02 11.96 18.15 39.83 188.33 2,029.09 0.77 —
Operating CF per Share
(3.08) (7.52) (5.57) (21.36) (20.63) (88.33) (1,795.54) (0.67) —
Capex per Share
(0.05) (0.53) (5.62) (1.68) (1.86) (9.00) (117.02) 0.00 —
Free Cash Flow per Share
(3.14) (8.05) (11.19) (23.04) (22.49) (97.33) (1,912.56) (0.67) —
Cash per Share
2.51 4.06 6.40 20.47 23.91 256.83 436.86 0.23 —
Shareholders Equity per Share
(0.33) 3.23 1.12 9.79 14.42 170.18 (18,606.53) (7.46) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
(0.33) 3.23 1.12 9.79 14.42 170.18 (18,606.53) (7.46) —
Free Cash Flow
(23.67) (52.09) (45.93) (48.51) (30.77) (23.54) (23.14) (17.68) —
Working Capital
15.08 25.17 6.27 30.50 14.65 54.02 (9.90) 5.45 —
Capital Expenditures
(0.40) (3.44) (23.06) (3.53) (2.55) (2.18) (1.42) (0.62) —
Net Current Asset Value
(57.42) (36.88) (54.83) (18.97) (12.76) 6.24 (257.47) (43.21) —
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Capex to Sales
0.00 0.05 0.47 0.09 0.05 0.05 0.06 0.00 —
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets
0.28 0.29 0.38 1.87 1.41 2.74 1.51 1.25 —
Cash ROIC
(37.01%) (62.34%) (69.45%) (54.66%) (49.27%) (17.96%) 12.59% 10.47% —
Accounts Receivable Turnover
10.03 8.76 7.70 8.76 5.75 4.42 6.84 5.69 —
Accounts Payable Turnover
6.34 6.08 5.64 8.46 5.74 4.12 4.67 3.39 —
Inventory Turnover
0.00 0.00 0.00 6.58 10.01 11.00 8.10 5.87 —
Average Days of Payables
67.24 51.42 82.17 43.45 19.88 148.73 103.18 73.40 —
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 57.99 —
Average Receivables
8.82 8.14 6.37 4.36 9.48 10.30 3.59 3.59 —
Average Payables
2.64 2.56 2.31 1.67 5.31 5.34 1.30 1.30 —
Average Inventory
— — — 2.15 3.05 2.00 0.75 0.75 —
Average Assets
92.36 98.17 96.00 84.50 98.58 83.05 42.05 19.53 —
Average Common Equity
9.21 12.73 12.59 20.17 30.45 (91.99) (211.58) (211.58) —

Fold the line items

Columns are period end dates